Circulating heart failure biomarkers beyond natriuretic peptides : review from the Biomarker Study Group of the Heart Failure Association (), European Society of Cardiology ()

Wouter C. Meijers, Antoni Bayés-Genís, Alexandre Mebazaa, Johann Bauersachs, John G.F. Cleland, Andrew J. S. Coats, James L. Januzzi, Alan S. Maisel, Kenneth McDonald, Thomas Mueller, A. Mark Richards, Petar Seferovic, Christian Mueller, Rudolf A. de Boer

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

97 Cites (Scopus)

Resum

New biomarkers are being evaluated for their ability to advance the management of patients with heart failure. Despite a large pool of interesting candidate biomarkers, besides natriuretic peptides virtually none have succeeded in being applied into the clinical setting. In this review, we examine the most promising emerging candidates for clinical assessment and management of patients with heart failure. We discuss high-sensitivity cardiac troponins (Tn), procalcitonin, novel kidney markers, soluble suppression of tumorigenicity 2 (sST2), galectin-3, growth differentiation factor-15 (GDF-15), cluster of differentiation 146 (CD146), neprilysin, adrenomedullin (ADM), and also discuss proteomics and genetic-based risk scores. We focused on guidance and assistance with daily clinical care decision-making. For each biomarker, analytical considerations are discussed, as well as performance regarding diagnosis and prognosis. Furthermore, we discuss potential implementation in clinical algorithms and in ongoing clinical trials.
Idioma originalAnglès
Pàgines (de-a)1610-1632
Nombre de pàgines23
RevistaEuropean Journal of Heart Failure
Volum23
DOIs
Estat de la publicacióPublicada - 2021

Fingerprint

Navegar pels temes de recerca de 'Circulating heart failure biomarkers beyond natriuretic peptides : review from the Biomarker Study Group of the Heart Failure Association (), European Society of Cardiology ()'. Junts formen un fingerprint únic.

Com citar-ho